Incannex Healthcare (IXHL) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Incannex Healthcare (IXHL) over the past year, losing 18.2% versus a loss of 75.3%. Talphera is the larger company by market cap ($56.1 million vs $40.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | TLPH |
|---|---|---|
| Share price | $3.20 | $1.08 |
| Market cap | $40.14M | $56.06M |
| 1-day change | +0.63% | +2.86% |
| YTD return | -70.20% | -5.26% |
| 1-year return | -75.31% | -18.18% |
| 5-year return | — | -94.71% |
| EPS (TTM) | $-1.66 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $1.57 |
| 52-week low | $2.49 | $0.69 |
| Distance from 52-week high | -78.54% | -31.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +483.75% | +189.81% |
| Average volume | 94.75K | 238.38K |
| Shares outstanding | 12.54M | 51.91M |
| Employees | 12 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed IXHL by 57.1 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
IXHL vs TLPH FAQ
Which is bigger, Incannex Healthcare or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $40.14M for Incannex Healthcare (IXHL).
Which stock has performed better over the past year, IXHL or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -75.31% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and Talphera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.